跳转至内容
Merck
所有图片(1)

文件

OP09

Sigma-Aldrich

Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801)

liquid, clone PAb1801, Calbiochem®

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.43

生物源

mouse

品質等級

抗體表格

purified antibody

抗體產品種類

primary antibodies

無性繁殖

PAb1801, monoclonal

形狀

liquid

包含

≤0.1% sodium azide as preservative

物種活性

human

應無反應活性

mouse, rat

製造商/商標名

Calbiochem®

儲存條件

do not freeze

同型

IgG1

運輸包裝

wet ice

儲存溫度

2-8°C

目標翻譯後修改

unmodified

基因資訊

human ... TP53(7157)

一般說明

Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 Ag14 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
Recognizes the ~53 kDa wild-type and mutant p53 protein in A-431 cells and breast carcinoma tissue.
This Anti-p53 (Ab-2) (Pantropic) Mouse mAb (PAb1801) is validated for use in Frozen Sections, Gel Shift, Immunoblotting, IP, Paraffin Sections for the detection of p53 (Ab-2) (Pantropic).

免疫原

Epitope: within amino acids 46-55 of human p53
Human
a human p53 fusion protein

應用

Frozen Sections (5 µg/ml)

Gel Shift (see comments)

Immunoblotting (2.5 µg/ml)

Immunoprecipitation (1 µg/sample)

Paraffin Sections (5 µg/ml, pepsin, trypsin, or heat pre-treatment required)

包裝

Please refer to vial label for lot-specific concentration.

警告

Toxicity: Standard Handling (A)

外觀

In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.

分析報告

Negative Control
SK-OV-3 cells or normal skin
Positive Control
A431 cells or breast carcinoma tissue

其他說明

El-Deiry, W.S., et al. 1994. Cancer Res.54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res.54, 4855.
Barak, Y., et al. 1993. EMBO J.12, 461.
Kastan, M.B., et al. 1992. Cell71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA89, 7491.
Lane, D.P. 1992. Nature358, 15.
Kastan, M.B., et al. 1991. Cancer Res.51, 6304.
Wild-type p53 has a short half-life and is present in low amounts in cells. For immunoprecipitation, increasing the amount of sample to be immunoprecipitated and applied to the gel may help visualize wild-type p53; short incubation times with 35S-Met (≤ 1 h) will help reduce background. For immunoblots of wild-type p53, maximize sensitivity by preconcentrating samples by immunoprecipitation with Cat. No. OP09, then immunoblot using Cat. No. PC35 and chemiluminescent detection. For a gel shift assay, use Cat. No. OP09L and resuspend in 100 µl buffer. Antibody should be titrated for optimal results in individual systems.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 产品选型工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

nwg

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Timothy Budden et al.
Oncotarget, 7(38), 60940-60953 (2016-08-04)
UVB exposure leads to DNA damage, which when unrepaired induces C>T transitions. These mutations are found throughout the melanoma genome, particularly in non-transcribed regions. The global genome repair (GGR) branch of nucleotide excision repair (NER) is responsible for repairing UV-induced
Shou-Ching Tang et al.
Breast cancer research and treatment, 84(3), 203-213 (2004-03-18)
BAG-1, a recently identified anti-apoptotic protein, is overexpressed in the majority of invasive breast carcinomas. Overexpression of BAG-1 is important for both multi-step oncogenesis and resistance of cancer cells to apoptosis induced by DNA-damaging alkylating agents. BAG-1 protein species are
James G Jackson et al.
Cancer cell, 21(6), 793-806 (2012-06-16)
Studies on the role of TP53 mutation in breast cancer response to chemotherapy are conflicting. Here, we show that, contrary to dogma, MMTV-Wnt1 mammary tumors with mutant p53 exhibited a superior clinical response compared to tumors with wild-type p53. Doxorubicin-treated
Timothy C Hallstrom et al.
Proceedings of the National Academy of Sciences of the United States of America, 100(19), 10848-10853 (2003-09-05)
Previous work has demonstrated a role for the E2F1 gene product in signaling apoptosis, both as a result of the deregulation of the Rb/E2F pathway as well as in response to DNA damage. We now show that the ability of
Lea Beltzig et al.
Cancers, 14(9) (2022-05-15)
First-line drug in the treatment of glioblastoma, the most severe brain cancer, is temozolomide (TMZ), a DNA-methylating agent that induces the critical damage O6-methylguanine (O6MeG). This lesion is cytotoxic through the generation of mismatch repair-mediated DNA double-strand breaks (DSBs), which

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门